Kornimate/medical-research-clean huggingface dataset:
investigation of the effectiveness of muscle inhibition and space correction techniques of kinesiotaping method in female patients with myofascial pain syndrome related to upper trapezius active trigger points

Conditions: Female Patients With Myofascial Pain Syndrome (MPS) Related to Upper Trapezius Active Trigger Points (TP)

Summary: to investigate the effectiveness of muscle inhibition and space correction techniques of kinesiotaping (kt) method; on pain, functional status and quality of life in female patients with myofascial pain syndrome (mps) related to upper trapezius active trigger points (tp) in comparison to control group and to determine the advantage of each technique over another.

the investigators conducted a prospective, randomized, controlled trial involving 93 female patients with mps related to upper trapezius tps and randomized the patients to kt treatment group with space correction technique and home exercise program (ksct, n=20), kt treatment group with muscle inhibition technique and home exercise program (kmit, n=24) and control group (cg, n=27) which received home exercise program only. patients were evaluated by numerical rating scale (nrs) for their average and maximum pain intensity, turkish version of neck disability index (ndi), and short form-36 (sf-36) scales. statistical tests were conducted at the 0.05 significance level for all outcome measures.

Eligibility criteria:
inclusion criteria: * being female * being aged between 18 and 45 years old * not being in menopausal period * having pain in upper trapezius region * determining a taut band in examination * having at least one active tp in this taut band * the pain produced by palpation of this tp is the pain that the patient complains * painfull restriction of cervical lateral flexion * having pain score 4 or more according to nrs * signing informed consent. exclusion criteria: * having major surgery or trauma related to the musculoskeletal system (primarily including the spine and upper extremity) * having any operative history including the head and neck region * having a neuromuscular disease * having an active rheumatic disease * having a systemic disease (diabetes, hypothyroidism, infection, malignancy...) * having any pathology related to musculoskeletal diseases -especially including the cervical region- (cervical discopathy, cervical spondylosis, pathologies related to shoulder joint and surrounding soft tissues, scoliosis, kyphosis, limb length discrepancy, polio sequelae, developmental hip dysplasia...) * having serious psychological problems (having score of 30 or more from beck depression inventory) * being obese (body mass index≥30 kg/m2) * having allergy to kinesiotapes

Keywords: myofascial pain syndrome, kinesiotaping, upper trapezius, home exercise program
caffeine, cypa12 and resistance exercise

Conditions: CYP1A2 Polymorphism; Caffeine and Resistance Exercise

Summary: introduction: several studies have evaluated and confirmed the ergogenic effect of acute caffeine intake on sports performance, specifically on strength and power performance. however, it remains to be elucidated how cyp1a2 polymorphism influences the acute effects of caffeine on this type of exercise. objectives: the present study aims to analyze the effects of acute caffeine intake on muscular strength, power, and endurance performance according to cyp1a2 polymorphism in men and women.


Eligibility criteria:
inclusion criteria: * age between ≥ 18 and ≤ 35 years. * body mass index (bmi) lower than 25 kg/m². * physically active subjects (≥150 min/week of moderate exercise). * healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise. * participants capable of performing the tests. exclusion criteria: * history of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism. * use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study. * body mass index (bmi) ≥ 25 kg/m². * having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study. * performing strenuous exercise within 48 hours prior to the tests. * failing to replicate the same food intake on the two experimental days. * consuming caffeine after 6 pm on the day prior to training or testing.
combination chemotherapy in treating patients with locally advanced or metastatic cancer of the pancreas

Conditions: Pancreatic Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more that one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combining gemcitabine and docetaxel in treating patients who have locally advanced or metastatic cancer of the pancreas.

objectives: i. determine the objective response rate of patients with pancreatic adenocarcinoma treated with combination gemcitabine and docetaxel. ii. determine the toxicity profile of this combination therapy in these patients. iii. assess the survival rate of these patients. outline: patients receive docetaxel iv over 1 hour followed by gemcitabine iv over 30 minutes. patients receive treatment every other week for 8 weeks (4 courses). patients may continue treatment in the absence of unacceptable toxicity or disease progression. patients are followed every 12 weeks until death. projected accrual: this study will accrue approximately 10 patients per month for a maximum of 33 patients.

Eligibility criteria:
disease characteristics: histologically confirmed adenocarcinoma or poorly differentiated carcinoma of the pancreas metastatic disease with at least 1 bidimensionally measurable lesion or locally advanced disease that is either recurrent or not amenable to surgery measurable disease outside of prior radiation port or disease progression within the port patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: not specified hematopoietic: absolute neutrophil count at least 1500/mm3 platelet count at least 125,000/mm3 hepatic: bilirubin no greater than upper limit of normal (uln) sgot no greater than 2.5 times uln (less than 3 times uln if liver metastases) renal: creatinine no greater than uln other: not pregnant or nursing fertile patients must use effective contraception prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy for metastatic disease at least 1 year since prior adjuvant chemotherapy prior chemoradiotherapy as initial therapy allowed endocrine therapy: not specified radiotherapy: see disease characteristics see chemotherapy at least 4 weeks since prior radiotherapy surgery: not specified

Keywords: stage iii pancreatic cancer stage iv pancreatic cancer recurrent pancreatic cancer adenocarcinoma of the pancreas
hilotherapy vs. kinesio taping in orthognathic surgery recovery

Conditions: Postoperative Edema; Postoperative Pain; Trismus; Orthognathic Surgery

Summary: this prospective randomized controlled trial aims to compare the effects of kinesio taping and hilotherapy on postoperative edema, pain, and trismus in patients undergoing bimaxillary orthognathic surgery.

orthognathic surgery frequently causes postoperative edema, pain, and trismus. the study compares two adjunctive therapies: kinesio taping and hilotherapy. forty-four patients without systemic disease, undergoing le fort i + bssro, will be randomly assigned to two groups. group 1 will receive kinesio taping for 5 days. group 2 will undergo hilotherapy for 48 hours. pain (vas), trismus (mouth opening), and edema (measured by both tape and 3d scanner) will be assessed at multiple postoperative time points. the goal is to determine the more effective intervention for postoperative recovery.

Eligibility criteria:
inclusion criteria: * patients scheduled to undergo bimaxillary orthognathic surgery (le fort i + bssro) * age between 18 and 50 years * no systemic disease * voluntary participation with signed informed consent exclusion criteria: * presence of systemic disease or immunosuppressive medication * known allergy to kinesio tape * inability to attend follow-up appointments * facial anatomical deformities preventing measurement

Keywords: hilotherapy kinesio taping orthognathic surgery postoperative complications postoperative recovery
rct comparing 2 radiotherapy hypofractionation schedules in breast cancer patients

Conditions: Radiotherapy Side Effect; Locoregional Recurrence

Summary: this is a prospective randomized phase iii trial to assess efficiency of two post mastectomy hypofractionation schedules (40 gy /15 fx / 3 weeks, 5 days per week vs 28.5 gy delivered in 5 once-weekly fractions of 5.7 gy each week) as adjuvant radiotherapy in female patients with breast cancer after mastectomy.

166 patients of breast cancer patients after mastectomy ( 83 patients in each arm ) will be randomize into 2 hypofractionation arms : arm a: 40 gy /15 fx / 3 weeks, 5 days per week . arm b: 28.5 gy delivered in 5 once-weekly fractions of 5.7 gy each week. simulation: patient will be simulated on ct simulator using breast wedge with angle. serials will be taken every 2 mm from upper neck down to mid abdomen. contouring: ctvcw, ctvrni will be contoured through rtog guidelines . ptv is added as 0.5 cm all around ctv. lungs, heart, brachial plexus, spinal cord, esophageus and thyroid will be contoured as oar. (www.rtog.org/corelab/contouringatlases/breastcanceratlas.aspx). d)dose constraints: arm a: ptv eval ( cw) : v90 % ≥ 90 %. - v105 % ≤ 5% - v107%≤ 3 %. ipsilateral lung: v20 less than 20-25% - v 8 less than 35%- contra lateral lung: v4 less 10 %. heart: v16 less than 5% (lt sided). v20 less than 5% (lt sided). v16 is 0%.(rt sided) v20 is 0% (rt sided). mean heart dose ≤ 320-400 cgy. contra lateral breast : d max≤ 240 cgy. v 144 cgy less than 5 %. scv : v90 % ≥ 90 %. thyroid : mean dose less than 35 gy - v30 less than 50 %. arm b: ptv eval ( cw) : v90 %≥ 90 %. - v105 %≤ 5% - v107%≤ 2 %. ipsilateral lung: v30%less than 15 -20% - v15% less than 30-35% - v5 % less than 50-55%. contra lateral lung : v5 % less than 5%. heart :v25 % less than 5 % - v5 % less than 30 - 35 %. contra lateral breast: v3 % less than 5 %. scv : v90 % ≥ 90 %. follow up: a)weekly follow up will be done during sessions then regular clinical exam every 3 months to assess : 1. acute and late toxicity regarding pain, pulmonary toxicity, dysphagia, skin toxicity and lymphedema.assessment will be done according to rtog and ctcv.5. 2. any local (chest wall) recurrence, regional (nodal) recurrence. b)annual mammogram. c)any another investigation (once indicated)

Eligibility criteria:
inclusion criteria: * invasive carcinoma of the breast. * complete microscopic excision of primary tumour and axillary dissection or slnb . * females with locally advanced breast cancer ( t3/t4 or n + or both ) who are candidate for neoadjvant chemotherapy regardless pathological stage after mastectomy. * patients with pathological stage (t3/ t4, +/- n+) or ( n+, any t) after upfront mastectomy. * able to comply with follow up. * written informed consent exclusion criteria: * patients do not match with inclusion criteria. * collagen vascular disease, specifically systemic lupus, or scleroderma. * pregnancy or lactation at the time of radiotherapy.

Keywords: post op radiotherapy mastectomy locoregional control
glybera registry, lipoprotein lipase deficient (lpld) patients

Conditions: Lipoprotein Lipase Deficiency; Familial Hyperlipoproteinemia Type 1; Familial Hyperchylomicronemia

Summary: lipoprotein lipase deficiency (lpld) is a rare autosomal recessive disorder, characterized by loss-of function mutations in the lpl gene, leading to the inability to produce functionally active lipoprotein lipase (lpl). lpl is the key enzyme in the metabolism of triglyceride (tg)-rich lipoproteins (chylomicrons (cm) and very low-density lipoproteins (vldl)). lpld results in extremely high concentrations of circulating tg-rich lipoproteins. no drug therapy for lpld is currently available. clinical management of lpld patients consists of severe dietary fat restriction and the use of medium-chain triglycerides to substitute for normal dietary fats. alipogene tiparvovec (glybera®) received marketing authorisation from the european commission on 25 october 2012. glybera® aims to correct lipoprotein lipase deficiency sufficiently to decrease the morbidity and lower the risk of inherent complications of lpld, in adult patients genetically diagnosed with lpld. the glybera registry is designed to collect the long-term safety and efficacy data of glybera®

all patients treated with glybera®, in a clinical trial and when glybera® was commercially available who are currently participating in the lpld registry (long term follow up of safety and efficacy in lpld), will be asked to continue their participation in this glybera registry to collect long-term safety and efficacy data.

Eligibility criteria:
inclusion criteria: * all patients treated with glybera®, either during their participation in a clinical trial or in the commercial setting till october 25th, 2017 (= expiration date of marketing authorization of glybera®), and * who are currently participating in the lpld registry exclusion criteria: * none
a trial investigating the influence of oral semaglutide on the pharmacokinetics of lisinopril and warfarin in healthy subjects

Conditions: Diabetes; Healthy

Summary: this trial is conducted in europe. the aim of the trial is to investigate the influence of oral semaglutide (nnc0113-0217) on the pharmacokinetics of lisinopril and warfarin in healthy subjects.


Eligibility criteria:
inclusion criteria: * male or female aged 18-75 years (both inclusive) at time of signing informed consent * body mass index 20.0-29.9 kg/m\^2 (both inclusive) * a good general health based on medical history, physical examination, and results of vital signs, electrocardiogram and laboratory safety tests performed during the screening visit, as judged by the investigator exclusion criteria: * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods. female of child bearing potential must use effective methods of birth control for the duration of the trial and for 5 weeks following last dose. only highly effective methods of birth control are accepted (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some intrauterine devices) * history of crohn's disease, ulcerative colitis, or other inflammatory bowel disease * hypertension (defined as sitting systolic blood pressure above 140 mmhg and/or diastolic blood pressure above 90 mmhg). if white-coat hypertension is suspected at the screening visit, a repeated measurement is allowed * any blood draw in excess of 50 ml in the past month, or donation of blood or plasma in excess of 400 ml within the 3 months preceding screening
treatment for elderly patients with high risk breast cancer

Conditions: Breast Cancer

Summary: this open-label, multicenter study explored primary and secondary prophylaxis treatment with a single, fixed-dose, subcutaneous (sc) injection of pegfilgrastim in elderly subjects with high-risk breast cancer receiving myelosuppressive chemotherapy. the primary objective was to provide preliminary information on the incidence of protocol defined neutropenic events in chemotherapy cycle 1.


Eligibility criteria:
inclusion criteria: - high-risk, stage ii-iii breast cancer suitable for treatment with up to 6 cycles of fec-100 - chemotherapy - histologically proven greater than or equal to 1 axillary nodes positive - oestrogen receptor negative or positive - chemotherapy naïve - ves 13 (vulnerable elders survey) score less than or equal to 3 - ecog performance status less than or equal to 2 - anc greater than or equal to 1.5 x 10\^9/l - platelets greater than or equal to 100 x 10\^9/l - adequate renal function (serum creatinine less than 1.5 x upper limit of normal (uln)) - before any study specific procedure the subject must give written informed consent for participation in the study exclusion criteria: - total serum bilirubin greater than uln according to institutional standard - clinically significant cardiac disease that would preclude the use of epirubicin (e.g., lvef (left ventricular ejection fraction)) less than 45% at rest by muga or echocardiogram - prior bone marrow or stem cell transplantation - any premalignant myeloid condition or any malignancy with myeloid characteristics (e.g., myelodysplastic syndromes, acute or chronic myelogenous leukaemia) - history of prior malignancy other than breast cancer with the exception of curatively treated basal cell carcinoma, in situ cervical carcinoma or surgically cured malignancies - prior radiation therapy - active infection or administration of systemic antibiotics or anti-infectives within 72 hours before start of chemotherapy - known hypersensitivity to e coli-derived products (e.g., filgrastim, humulin®, insulin, l-asparaginase, humatrope®, growth hormone, intron a®) - previous exposure to pegfilgrastim or previous entry into this study - known hiv infection - inability to understand the nature of the study and provide written informed consent - subject currently enrolled in another investigational device or drug trial(s) or has received other investigational agent(s), with the exception of placebo-treated subjects, within the last 30 days - concerns for subject's compliance with the protocol procedures

Keywords: aged, granulocyte colony-stimulating factor combined modality therapy, neutropenia pegfilgrastim, neulasta® fec-100, antineoplastic agents breast cancer, female
evaluating the efficacy of culturally adapted ict-sad

Conditions: Social Anxiety; ICT

Summary: the study will adapt and implement a pakistani version of internet-delivered cognitive therapy for social anxiety disorder (ict-sad), assessing its effectiveness in reducing social anxiety symptoms among pakistani individuals.

the study will adapt and implement a pakistani version of internet-delivered cognitive therapy for social anxiety disorder (ict-sad), assessing its effectiveness in reducing social anxiety symptoms among pakistani individuals. this randomized controlled trial will involve culturally tailored online therapy modules, therapist support, and regular progress assessments. the goal is to evaluate the efficacy of ict-sad in a pakistani context, comparing outcomes to a control group. the primary outcome measure is the self-report liebowitz social anxiety scale, and secondary outcomes include other measures of social anxiety symptoms and processes, general mood and functioning, and response to treatment

Eligibility criteria:
inclusion criteria: * primary diagnosis of sad based on the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) * aged 18-75 years * regular, access to an appropriate internet device * resident of pakistan and can write and speak urdu * participants not currently undertaking other structured psychological therapy during the trial exclusion criteria: * current psychosis, bipolar disorder, antisocial personality disorder, or alcohol/substance use disorder * active suicidal ideation with intent or plan * previously received ct or cognitive behavioral therapy for sad
study to evaluate the efficacy and safety of camrelizumab and apatinib in patients with gc/gejc

Conditions: Gastric Cancer

Summary: this is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. the primary study hypotheses are that camrelizumab (shr-1210) combined with apatinib prolongs overall survival (os) for participants with tumors that show positive programmed cell death ligand 1 (pd-l1) expression.


Eligibility criteria:
inclusion criteria: 1. histologically- or cytologically-confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma. 2. confirmed metastatic or locally advanced, unresectable disease. 3. progression on or after prior first-line therapy containing any platinum/fluoropyrimidine or platinum/taxane doublet. 4. willing to provide tumor tissue for pd-l1 biomarker analysis. 5. human epidermal growth factor receptor 2 (her-2/neu) status known and participants with her2/neu positive tumors show documentation of previous treatment containing trastuzumab. 6. ecog performance status of 0 to 1. 7. life expectancy of more than 12 weeks. 8. signing the informed consent forms. 9. adequate bone marrow, liver and renal function. exclusion criteria: 1. squamous cell or undifferentiated gastric cancer. 2. known active central nervous system (cns) metastases and/or carcinomatous meningitis. 3. subjects with an active, known or suspected autoimmune disease. patients with type i diabetes who are receiving a stable dose of insulin, hypothyroidism who only needs hormone replacement therapy, and skin diseases (such as eczema, vitiligo, or psoriasis) that do not require systemic treatment and do not have acute deterioration within 1 year before the screening period, are allowed. 4. clinically significant cardiovascular and cerebrovascular diseases. 5. subjects with high blood pressure who cannot be controlled well with antihypertensive drugs. 6. previous digestive tract bleeding history within 3 months or evident gastrointestinal bleeding tendency. 7. arterial / venous thrombosis events, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism, occurred within the first 6 months of randomization. 8. subjects who have previously received anti-pd-1 / pd-l1 monoclonal antibody, anti-ctla-4 monoclonal antibody, and vegfr small molecule inhibitor therapy. 9. prior systemic chemotherapy, radiotherapy and surgery within 4 weeks before the study drug administration, or any unresolved aes \> common terminology criteria for adverse events (ctcae) grade 1.
the comparative effectiveness dementia & alzheimer's registry

Conditions: Alzheimer Disease; Mild Cognitive Impairment

Summary: to evaluate the effectiveness of using clinical precision medicine to develop lifecourse interventions for alzheimer's disease (ad) prevention and treatment. anthropometrics, blood biomarkers (including genetics), and cognition will measured longitudinally to assess the comparative effectiveness of clinical care.

the comparative effectiveness dementia \& alzheimer's registry (cedar) project is a prospective, observational registry of adult patients at-risk for, or with, a diagnosis of dementia due to alzheimer's disease (ad) or other neurodegenerative dementias. the purpose of this study is to develop a research repository, or database, for information collected during routine medical care of people with normal memory and family history of ad, or with memory loss or other changes in thinking. the registry will help generate empirical evidence that improves knowledge and informs care decisions about risk reduction for dementia due to ad, and about the effectiveness of a clinical precision medicine intervention. using a life course approach to comparative effectiveness research will enable investigators to analyze the effects of evidence-based multidomain interventions on cognition, biomarkers of ad risk, and calculated ad risk across the pre-dementia spectrum of ad.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * family history of alzheimer's disease and no cognitive complaints or subjective cognitive decline or preclinical ad or mild cognitive impairment due to ad or other conditions exclusion criteria: * none